NCHR supports the proposed FDA rule, which aims to reclassify wound dressings and liquid wound washes containing antimicrobials based on their level of antimicrobial resistance (AMR), with higher-risk products categorized as Class III. This change is crucial for mitigating the public health threat posed by AMR, ensuring the appropriate use of these medical devices, and ultimately improving patient outcomes.
Read More »On Medical Treatments & Products
Statement of Dr. Diana Zuckerman on Behalf of the National Center for Health Research FDA Advisory Committee Meeting on AMX0035 for ALS
September 7, 2022 Diana Zuckerman testified on behalf of NCHR at the FDA Advisory Committee hearing about the poor evidence foe Amylyx drug AMX0035 for the treatment of ALS, and how approving this drug would undermine other ALS clinical trials that are underway.
Read More »NCHR Agrees with CDC Draft Recommendation to Remove Liraglutide and Pertuzumab from the National Institute for Occupational Safety and Health Hazardous Drugs in Healthcare Settings List
February 15th, 2024: NCHR supports the CDC recommendation to remove Liraglutide and Pertuzumab drugs from the NIOSH List of Hazardous Drugs in Healthcare Settings. We agree that due to the to the drugs’ low bioavailability and limited risk of occupational exposures these drugs are unlikely to pose a harm to healthcare workers.
Read More »NCHR’s Comment on EPA’s Proposed Lead and Copper Rule Improvements (LCRI)
February 2024: In its public comment, NCHR supported EPA’s proposed lead and copper rule improvements (LCRI) and suggested strengthening safeguards such as lowering the action lead level to 5 ppb or less, more attention to schools, daycares, and afterschool facilities, better enforcement, and not replacing lead pipes with PVC or other dangerous pipes.
Read More »NCHR Comments on USPSTF Draft Recommendations on Interventions for Adolescents with a High Body Mass Index
January 16, 2024: NCHR strongly supports USPSTF’s draft recommendation on using behavioral interventions to manage unhealthy weight gain in adolescents over six years of age with a body mass index at the 95th percentile for their age and sex. More research is needed to clearly show the safety and efficacy of weight loss medications in this patient population.
Read More »